𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pilot study of ribavirin and interferon-β for chronic hepatitis B

✍ Scribed by Shinichi Kakumu; Kentaro Yoshioka; Takaji Wakita; Tetsuya Ishikawa; Masahiro Takayanagi; Yasuyuki Higashi


Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
586 KB
Volume
18
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis


YASUYUKI HIGASHI

Ribavirin is a nucleoside analog that inhibits the replication of many DNA and RNA viruses. To evaluate the efficacy of oral ribavirin, we randomly assigned 24 HBeAg-positive patients with chronic active hepatitis to a 12-wk course of treatment with 0.8 to 1.0 gm/ribavirin day, 3 mU interferon-p three times a week intravenously or a combination of those drugs. Ribavirin, alone and in combination with interferon-p, decreased hepatitis B virus levels in most patients, and mean serum hepatitis B virus DNA and DNA polymerase levels at the end of treatment were approximately half of baseline levels (p < 0.05). Interferon alone exerted the most inhibitory effect on hepatitis B virus activity (p < 0.01). During ribavirin treatment, changes in serum aminotransferase values varied considerably and the mean values did not change significantly, although interferon alone and the combination of interferon and ribavirin were associated with significant reductions in serum aminotransferase activities. Ribavirin was well tolerated, but we transiently reduced the dosage in two cases because of mild hemolytic anemia, although all patients completed the treatment schedule. The combination of interferon and ribavirin did not appear to result in greater toxicity. During the follow-up period (6 to 9 mo), HBeAg and hepatitis B virus DNA disappeared in one patient treated with ribavirin, in two treated with interferon and in two given the combination. These results indicate that ribavirin suppresses hepatitis B virus replication, although its effect is less than that of interferon, and that it may be useful as adjunctive therapy for chronic hepatitis B. Simultaneous admin-


📜 SIMILAR VOLUMES


A pilot study of ribavirin therapy for c
✍ Adrian M. di Bisceglie; Michiko Shindo; Tse-Ling Fong; Michael W. Fried; Mark G. 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 541 KB

Interferon-alpha therapy is of proven efficacy in chronic hepatitis C, but it is not universally effective and may be associated with intolerable side effects. Ribavirin is a nucleoside analog with a broad spectrum of antiviral action. We conducted an uncontrolled pilot study of ribavirin therapy in

Merimepodib, pegylated interferon, and r
✍ Vinod K. Rustgi; William M. Lee; Eric Lawitz; Stuart C. Gordon; Nezam Afdhal; Fr 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB 👁 1 views

on behalf of the MErimepodib TRiple cOmbination (METRO) study group Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC) when combined with pegylated interferon alfa 2a (Peg-IFN-a

Interferon α-2b with and without ribavir
✍ Chun-Jen Liu; Ming-Yang Lai; You-Chen Chao; Li-Ying Liao; Sien-Sing Yang; Tun-Je 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB 👁 1 views

To study whether interferon (IFN) ␣ and ribavirin combination therapy has a beneficial effect for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B, we enrolled 119 such patients in a randomized study. Fifty-nine patients received 5 million units of IFN-␣2b daily for 4 weeks followed by 5 m

Pegylated interferon and ribavirin thera
✍ F. Legrand-Abravanel; F. Nicot; A. Boulestin; K. Sandres-Sauné; J.P. Vinel; L. A 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

## Abstract Hepatitis C Virus (HCV) is classified into six genotypes. Genotype 4 is now spreading in Europe, especially among drug users, who are often infected with both HCV and the human immunodeficiency virus (HIV). Previous studies have shown that HCV‐4 responds poorly to interferon. Pegylated